The Lancet

Progress in outcomes for patients with metastatic squamous non-small-cell lung cancer

The use of immunotherapy in patients with various types of cancer has led to dramatic increases in survival. Increased median ...
JSTOR Daily

Arterial instillation of rapamycin in treatment of rabbit hepatic xenograft tumors and its effects on VEGF, iNOS, HIF-1α, Bcl-2, Bax expression and microvessel density

Science Progress (1933-), Vol. 104, No. 3 (2021), pp. 1-14 (14 pages) Hepatocellular carcinoma is one of the leading causes of malignant tumor related death word wide with poor prognosis. Chemotherapy ...
Ophthalmology Times

Anti-VEGF innovations in retinal disease: From molecules to medicine

Second-generation anti-VEGF agents, like aflibercept 8 mg and faricimab, show improved efficacy and treatment durability in ...

AAO 2025: EYP-1901 continues to show promise in DME and wAMD

While anti-VEGF therapies remain the current standard of care, many DME patients experience suboptimal responses due to non-VEGF-related disease mechanisms.
Yahoo

Blocking PD-1 and VEGF: The bispecific cancer drugs that could best Keytruda

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Merck & Co.’s cancer immunotherapy Keytruda is one of ...